Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 27 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
REINE PHARMA from Brussel, company number BE0643728226, closed financial year 2025 with a result of € 53,748 after tax. For that financial year REINE PHARMA recorded a gross margin of € 326,480 and equity of € 125,834. Compared with financial year 2024, the result moved from € 140,408 to € 53,748. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2026.
€ 125,834
▲ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 53,748
▼ 62% vs 2024
Profit after tax over the fiscal year.
€ 31,093
▼ 53% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 24,000 paid out
45 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
2.6
Average over the fiscal year, from the social balance sheet.
€ 168,881
▲ 9% vs 2024
€ 65,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 8,636
▲ 29% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 15,054
▼ 75% vs 2024
Loans from banks and other lenders, long and short.
€ 184,255
▼ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,159
▲ 7% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 322,918 | € 310,848 | € 408,207 | € 326,480 | ▼ 20% |
| Profit after taxes | € 85,721 | € 65,392 | € 140,408 | € 53,748 | ▼ 62% |
| Equity | € 37,287 | € 37,679 | € 96,086 | € 125,834 | ▲ 31% |
| Total debts | € 1,111,112 | € 1,091,782 | € 909,449 | € 903,005 | ▼ 1% |
| Cash | € 194,052 | € 177,164 | € 66,587 | € 31,093 | ▼ 53% |
| Land & buildings | € 345,455 | € 334,091 | € 322,727 | € 311,364 | ▼ 4% |
| Retained profit | € 18,687 | € 19,079 | € 77,486 | € 107,234 | ▲ 38% |
| Dividend | € 65,000 | € 65,000 | € 82,000 | € 24,000 | ▼ 71% |
| Bank debt | € 148,553 | € 104,448 | € 59,951 | € 15,054 | ▼ 75% |
| Balance sheet total | € 1,148,399 | € 1,129,461 | € 1,005,535 | € 1,028,839 | ▲ 2% |
| Employees (FTE) | 2.6 | 2.6 | 0 | 2.6 |
Key figures of REINE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to REINE PHARMA?
What happened at REINE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 53,748 (▼ 62% vs 2024). filed late Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 85,721 profit in 2022 to € 53,748 profit in 2025.
Paid € 32,899 in corporate taxes since 2022.
Best year ever: 2024, with € 140,408 profit.
On average € 125,600 of value added per employee in 2025.
A new publication or filing at REINE PHARMA? We notify you, reason included.
Follow REINE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind REINE PHARMA is Masy Holding Besloten Vennootschap. Masy Holding Besloten Vennootschap is also behind Masy Pharma.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Bergstraat 25
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0643.728.226
- VAT number
- BE 0643.728.226
- Registered office
- Bergstraat 25, 1000 Brussel
- Names & denominations
- REINE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 November 2015
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Overige detailhandel in voedingsmiddelen, neg
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.